Gordon Jones, Chief Operating Officer of DPG Distribution, added, "DPG is very excited to represent RapiMed(R) in the North American market. RapiMed(R) has the potential to experience great success penetrating the massive market for children's pain relievers because of its speed, effectiveness, dosing accuracy and safety. Currently, we believe a very large opportunity exists for a new, superior product like RapiMed(R) to be introduced and capture significant market share. DPG looks forward to a long and profitable partnership with ScripsAmerica."\
SCRC ShockNawe!!!!!!!!!!!! Tut
Market Data 
Markets 
AI
